CoChat

Toward improved in vitro models of human cancer

Open access
Ayuso, Jose M., Park, Keon-Young, Virumbrales-Muñoz, María, Beebe, David J. · 2021 · APL Bioengineering

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Abstract

Cancer is a leading cause of death across the world and continues to increase in incidence. Despite years of research, multiple tumors (e.g., glioblastoma, pancreatic cancer) still have limited treatment options in the clinic. Additionally, the attrition rate and cost of drug development have continued to increase. This trend is partly explained by the poor predictive power of traditional in vitro tools and animal models. Moreover, multiple studies have highlighted that cell culture in traditional Petri dishes commonly fail to predict drug sensitivity. Conversely, animal models present differences in tumor biology compared with human pathologies, explaining why promising therapies tested in animal models often fail when tested in humans. The surging complexity of patient management with the advent of cancer vaccines, immunotherapy, and precision medicine demands more robust and patient-specific tools to better inform our understanding and treatment of human cancer. Advances in stem cell biology, microfluidics, and cell culture have led to the development of sophisticated bioengineered microscale organotypic models (BMOMs) that could fill this gap. In this Perspective, we discuss the advantages and limitations of patient-specific BMOMs to improve our understanding of cancer and how these tools can help to confer insight into predicting patient response to therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1063/5.0026857

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIG. 1. Schematic representation of a comparison among bioengineered microscale organotypic models (BMOMs), in vitro and in vivo models. BMOMs are a balanced middle ground between the advantages of in vitro models (purple) and the advantages of in vivo models (green). Further, the leverage of microscale technologies comes with advantages over both in vitro and in vivo models (red).
FIG. 1. Schematic representation of a comparison among bioengineered microscale organotypic models (BMOMs), in vitro and in vivo models. BMOMs are a balanced middle ground between the advantages of in vitro models (purple) and the advantages of in vivo models (green). Further, the leverage of microscale technologies comes with advantages over both in vitro and in vivo models (red).CC BY · PubMed Central
FIG. 2. The precision medicine “puzzle.” We envision that precision medicine will rely on the convergence of four main pillars: patients, animal models, organotypic microscale models, and computational models. Interdisciplinary and collaborative work will be necessary to achieve this goal. Further, active collaboration of universities, industry, patient advocate groups and the government remain to be pieced into this concerted effort.
FIG. 2. The precision medicine “puzzle.” We envision that precision medicine will rely on the convergence of four main pillars: patients, animal models, organotypic microscale models, and computational models. Interdisciplinary and collaborative work will be necessary to achieve this goal. Further, active collaboration of universities, industry, patient advocate groups and the government remain to be pieced into this concerted effort.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. 2016, Introduction to BioMEMS
  2. 2016, Systems Biology for Organotypic Cell Cultures
  3. U.S. Environmental Protection Agency, Office of Research and Development,, 2015, Organotypic Culture Models for Predictive Toxicology Research Centers

Cited by

See all 40

Metadata

Authors
Ayuso, J. M., Park, K.-Y., Virumbrales-Muñoz, M., & Beebe, D. J.
Affiliations
  • Department of Biomedical Engineering, University of Wisconsin 1 , Madison, Wisconsin 53705, USA
  • University of California, San Francisco (US)
  • University of Wisconsin–Madison (US)
Corresponding author
Beebe, David J.
Venue
APL Bioengineering
Published
2021-01-21
Volume
5
Issue
1
Pages
010902-010902
ISSN
2473-2877 (ISSN-L)
OpenAlex
W3122854086
Cited by
40
References
96
Citations by year
2026: 4 · 2025: 1 · 2024: 7 · 2023: 5 · 2022: 18 · 2021: 4
FWCI
2.58
Type
journal article
Language
en
Open access
Licence
Locations
  • APL Bioengineering (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Wisconsin Head and Neck Cancer SPORE (P50DE026787)
  • Morgridge Institute for Research (-)
  • National Cancer Institute (R01EB010039, 5T32HL110853-07)
  • University of Wisconsin Carbone Cancer Center (P30CA014520)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
Keywords
in vitro tumor model, drug response prediction, translational oncology, microfluidics, glioblastoma, pancreatic cancer, precision medicine, cancer immunotherapy, cancer vaccines, drug development attrition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.